• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease

Opinion
Video

Panelists discuss how hesitancy in prescribing amyloid-targeting therapies stems from multiple factors including concerns about ARIA adverse effects, modest clinical efficacy data, high treatment costs and limited insurance coverage, logistical challenges of regular infusions and monitoring, infrastructure requirements for specialized imaging, uncertainty about long-term benefits, and the need for careful patient selection within appropriate disease stages.

Related Videos
Galen Shearn-Nance, BS
5 experts are featured in this series
4 experts are featured in this series.
5 experts are featured in this series
Dr Johnie Rose
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
Andrew Evens, DO
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.